Bevacizumab-induced vessel normalization hampers tumor uptake of antibodies - Response

Cancer Research

Volumn 73, Issue 23, 2013, Pages 7147-7148

  Arjaans, Marlous ^a   Oosting, Sjoukje F ^a   Schröder, Carolina P ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY B20 4.1; MONOCLONAL ANTIBODY DC101; PANITUMUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIBODY RESPONSE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; COLORECTAL CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LETTER; LIVER METASTASIS; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERICYTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT RESPONSE; VASCULARIZATION;

EID: 84890306325     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2532     Document Type: Letter

References (10)

1. Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013;73:3347-55.
2. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012;109:17561-6.
3. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013;31:2205-18.
4. Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 2012;11:752-62.
5. Heskamp S, Boerman OC, Molkenboer-Kuenen DM, Oyen WJG, van der Graaf WTA, van Laarhoven HWM. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulinlike growth factor 1 receptor antibodies. Int J Cancer 2013;133:307-14.
6. 89Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment. J Clin Oncol 30, 2012 (suppl; abstr 10581).
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
9. van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of antiangiogenic drugs. Cancer Cell 2012;21:82-91.
10. 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal liver metastases. Nucl Med Commun 2011;32:343-7.